Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Public ClinicalTrials.gov record NCT00170469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
Study identification
- NCT ID
- NCT00170469
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2005
- Primary completion
- Jan 31, 2007
- Completion
- Jan 31, 2007
- Last update posted
- Sep 14, 2008
2005 – 2007
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Greater Huntsville Family Practice, PC | Huntsville | Alabama | 35802 | — |
| Discovery Alliance, Inc. | Mobile | Alabama | 36606 | — |
| Accelovance | San Diego | California | 92108 | — |
| Accelovance | Washington D.C. | District of Columbia | 20006 | — |
| Florida Medical Research Institute | Gainesville | Florida | 32607 | — |
| Accelovance | Melbourne | Florida | 32935 | — |
| Miami Research Associates | South Miami | Florida | 33143 | — |
| Accelovance | Orland Park | Illinois | 60462 | — |
| Accelovance | South Bend | Indiana | 46601 | — |
| Accelovance | Oklahoma City | Oklahoma | 73112 | — |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73120 | — |
| McKenzie Medical Center | McKenzie | Tennessee | 38201 | — |
| PharamTex Research, Inc. | Amarillo | Texas | 79106 | — |
| Accelovance | Houston | Texas | 77024 | — |
| Metropolitan Research | Fairfax | Virginia | 22031 | — |
| Carilion Medical Associates | Galax | Virginia | 24333 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00170469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2008 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00170469 live on ClinicalTrials.gov.